Werewolf Therapeutics Inc (HOWL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $47.64M
Last updated: Nov 17, 2026 at 4:21 PM ET
Werewolf Therapeutics Inc (HOWL) Statistics
Werewolf Therapeutics (HOWL) has a market cap of $47.64M and an enterprise value of $5.77M. It kept -133.90% of revenue as net income over the last 12 months. It holds $41.87M more cash than debt, 87.89% of its market cap.
Total Valuation
Enterprise value is 87.89% below the market cap, as cash exceeds debt.
| Market Cap | $47.64M |
|---|---|
| Enterprise Value | $5.77M |
| Latest price (Nov 17, 2026) | $1.05 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.4x and 7.5x. Its year-end P/S ranged from 3.7x to 34.4x from 2022 to 2024.
| P/S Ratio | 2.4x |
|---|---|
| P/B Ratio | 7.5x |
Price Statistics
The stock is up 14.35% over 52 weeks and trades 6.06% above its 50-day average.
| Beta (1Y) | 1.56 |
|---|---|
| 52-Week Change | +14.35% |
| 1-Month Change | +0.96% |
| 3-Month Change | +156.54% |
| 6-Month Change | +145.10% |
| 5-Year Change | -93.71% |
| Total Return (1Y) | +14.35% |
| Total Return (3Y CAGR) | -23.00% |
| Total Return (5Y CAGR) | -42.27% |
| Max Drawdown (1Y) | -72.00% |
| Max Drawdown (3Y) | -96.11% |
| Sharpe Ratio (1Y) | 0.11 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $0.99 |
| 200-Day Average | $0.70 |
| 52-Week Range | $0.27 to $1.20 |
| RSI (14 Days) | 57.0 |
| Average Volume (20 Days) | 343.79K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.19x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.19x |
|---|---|
| Quick Ratio | 1.19x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -416.04% over the last 12 months, against a 5-year average of -90.31%.
| Return on Equity (ROE) | -416.04% |
|---|---|
| Return on Assets (ROA) | -65.77% |
| Return on Capital Employed (ROCE) | -340.45% |
| ROE (5Y Average) | -90.31% |
| ROA (5Y Average) | -45.21% |
| ROIC (5Y Average) | -50.58% |
| Asset Turnover | 0.34x |
Scores
HOWL has an Altman Z-Score of -16.46, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -16.46 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $21.00M over the last 12 months.
| Revenue | $21.00M |
|---|---|
| Gross Profit | $20.60M |
| Operating Income | -$25.59M |
| Pretax Income | -$28.12M |
| Net Income | -$28.12M |
| EBITDA | -$18.28M |
| EBIT | -$23.01M |
| Reported EPS (TTM) | -$0.57 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 15.81% of the $42.75M in total assets.
| Cash and Equivalents | $41.87M |
|---|---|
| Total Debt | $0 |
| Net Cash | $41.87M |
| Net Cash Per Share | $0.86 |
| Working Capital | $6.76M |
| Shareholder Equity | $6.76M |
| Book Value Per Share | $0.14 |
| Total Assets | $42.75M |
| Total Liabilities | $35.99M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$23.96M |
|---|---|
| FCF Per Share | -$0.49 |
| Depreciation and Amortization | $4.73M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -121.83%.
| Gross Margin | 98.10% |
|---|---|
| Operating Margin | -121.83% |
| Pretax Margin | -133.90% |
| Net Margin | -133.90% |
| EBITDA Margin | -87.05% |
| EBIT Margin | -109.58% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -58.29% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -58.29% |
Dividends and Yields
HOWL does not pay a dividend.
| Buyback Yield | -4.64% |
|---|---|
| Shareholder Yield | -4.64% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HOWL
What is HOWL's market cap?
Werewolf Therapeutics has a market cap of $47.64M. Its enterprise value, which adds debt and subtracts cash, is $5.77M.
How many shares of HOWL are outstanding?
Werewolf Therapeutics has 48.60M shares outstanding. The count is up 6.10% from a year earlier.
Does HOWL pay a dividend?
No. Werewolf Therapeutics does not pay a dividend.
How much debt does HOWL have?
Werewolf Therapeutics has $0 of total debt and $41.87M of cash and equivalents, a net cash position of $41.87M.
HOWL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors